Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab.
Blood Cancer J
; 11(9): 151, 2021 09 14.
文章
在 英语
| MEDLINE | ID: covidwho-1408475
ABSTRACT
The ability of patients with hematologic malignancies (HM) to develop an effective humoral immune response after COVID-19 is unknown. A prospective study was performed to monitor the immune response to SARS-CoV-2 of patients with follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), chronic lymphoproliferative disorders (CLD), multiple myeloma (MM), or myelodysplastic/myeloproliferative syndromes (MDS/MPN). Antibody (Ab) levels to the SARS-CoV-2 nucleocapsid (N) and spike (S) protein were measured at +1, +3, +6 months after nasal swabs became PCR-negative. Forty-five patients (9 FL, 8 DLBCL, 8 CLD, 10 MM, 10 MDS/MPS) and 18 controls were studied. Mean anti-N and anti-S-Ab levels were similar between HM patients and controls, and shared the same behavior, with anti-N Ab levels declining at +6 months and anti-S-Ab remaining stable. Seroconversion rates were lower in HM patients than in controls. In lymphoma patients mean Ab levels and seroconversion rates were lower than in other HM patients, primarily because all nine patients who had received rituximab within 6 months before COVID-19 failed to produce anti-N and anti-S-Ab. Only one patient requiring hematological treatment after COVID-19 lost seropositivity after 6 months. No reinfections were observed. These results may inform vaccination policies and clinical management of HM patients.
全文:
可用
采集:
国际数据库
资料库:
MEDLINE
主要主题:
Hematologic Neoplasms
/
Immunity, Humoral
/
Rituximab
/
SARS-CoV-2
/
COVID-19
研究类型:
队列研究
/
观察性研究
/
预后研究
话题:
长Covid
/
疫苗
限制:
成人
/
年老的
/
女性
/
人类
/
男性
/
中年
国家/地区名称主题:
欧罗巴
语言:
英语
期刊:
Blood Cancer J
年:
2021
类型:
文章
所属国家:
S41408-021-00546-9
相关文档
MEDLINE
...
LILACS
LIS